Buprenorphine is critical for expanding treatment availability to individuals with an opioid use disorder (OUD) because it can be prescribed by primary care clinicians. 1 However, buprenorphine is underused, and a contributing factor may be insurance company cost-control measures, such as prior authorization or step therapy. These policies, which require prescribers to obtain insurance approval prior to dispensing, may delay or disrupt treatment for patients with OUD vulnerable to relapse. For the more than 300 000 Medicare beneficiaries with OUD in 2013 (approximately 14% of 2.1 million US individuals with OUD), 1, 2 access to buprenorphine is important because methadone maintenance has historically not been a covered benefit. 3 We evaluated trends in buprenorphine coverage in the Medicare Part D program.
Methods | We analyzed Medicare Part D prescription drug plan formulary files from January 2007, 2012, and 2018 to characterize changes in coverage of buprenorphine products for OUD. Formulary files contain coverage details, including prior authorization and step therapy requirements, for both standalone and Medicare Advantage Part D plans. Using plan enrollment as weights, we estimated coverage and restrictions for each buprenorphine product using Stata version 15.1 (StataCorp). We used the Cochrane-Armitage trend test to evaluate changes in weighted proportions over time with 2-tailed P < .05 indicating statistical significance. We excluded plans with fewer than 11 enrollees because their data are suppressed. In 2016, 98% of Medicare Part D buprenorphine use was brand-name buprenorphinenaloxone sublingual films (70%), generic buprenorphinenaloxone sublingual tablets (16%), or generic buprenorphine sublingual tablets (12%). 4 Therefore, we focused on brandname and generic versions of these products. We also estimated the number of plans covering any buprenorphine Step therapy Step therapy Also, we evaluated the same policies for the most frequently prescribed long-acting (extended-release morphine sulfate) and short-acting (hydrocodone or acetaminophen) opioids in the Medicare program. 4 Results | The proportion of plans covering brand-name buprenorphine-naloxone sublingual tablets or films declined from all plans offering coverage to 74% (95% CI, 70%-77%) of plans in 2018 (Table; P < .001). Generic buprenorphinenaloxone tablets, which were approved in 2013, were covered by 73% (95% CI, 69%-77%) of plans in 2018. Brandname buprenorphine tablets, which were discontinued in 2011, were covered by 94% (95% CI, 92%-96%) of plans in 2007. Generic buprenorphine tablets, which were first available in 2010, were covered by all plans in 2018. Among plans offering coverage, prior authorization requirements for brand-name buprenorphine-naloxone tablets or films increased from 16% (95% CI, 13%-19%) of plans in 2007 to 58% (95% CI, 53%-63%) in 2018 (P < .001). Prior authorization was required by 57% (95% CI, 52%-62%) of plans in 2018 covering generic buprenorphine-naloxone tablets. Prior authorization was required by 13% (95% CI, 11%-16%) of plans in 2007 covering brand-name buprenorphine sublingual tablets. Although generic buprenorphine had the lowest cost ($80) in 2018, 66% (95% CI, 62%-70%) of plans required prior authorization.
Step therapy was required in 0% to 1% of plans.
The proportion of plans covering any buprenorphine product without restriction declined from 89% (95% CI, 87%-91%) in 2007 to 35% (95% CI, 31%-39%) in 2018 (P < .001). By comparison, 93% to 100% of plans covered the most frequently used prescription opioid analgesics without coverage restrictions during the study period.
Discussion | Although buprenorphine coverage in Medicare Part D plans was high throughout the study period, prior authorization requirements increased. In 2018, 65% of plans restricted coverage for all forms of buprenorphine. The reasons for restrictions on buprenorphine might reflect inaccurate perceptions of drug risk, societal norms related to the stigma of addiction, or financial considerations.
Historically, payers use prior authorization and step therapy policies to control costs; however, two-thirds of plans had prior authorization policies on lower-cost generic buprenorphine in 2018. Limitations of this study include a lack of data on approval criteria for restrictions and rebates paid to plans.
Effective in 2020, the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act will expand Medicare coverage to include methadone treatment through opioid treatment programs. 3 However, access to OUD treatment for Medicare beneficiaries could immediately be improved by requiring Part D plans to remove coverage-related barriers. Step therapy 
Performance of the Centers for Medicare & Medicaid Services' Opioid Overutilization Criteria for Classifying Opioid Use Disorder or Overdose
To address the growing problem of opioid overuse and abuse in the Medicare population, the Centers for Medicare & Medicaid Services (CMS) launched an Overutilization Monitoring System in 2013, requiring its Part D plan sponsors to identify beneficiaries who are at high risk of opioidrelated adverse events based on opioid overutilization criteria and to implement interventions. 1 Whether the criteria, which depend on prescription-dispensing data, are accurate as a clinical marker for classifying beneficiaries with opioid use disorder (OUD) or overdose is unknown.
Methods | We used the 5% Medicare sample from 2011 through 2014 to estimate the sensitivity, specificity, and positive predictive value of the CMS opioid overutilization criteria in correctly identifying prescription opioid users at risk of OUD or overdose in three 6-month cycles (ie, Januar y 1-June 30, April 1-September 30, and July 1-December 31) in each calendar year. We studied the performance measures over time, hypothesizing that accuracy might change with increasing efforts to combat the opioid crisis. 2 Concordant with the most recent (2017) reporting requirements for Part D plans, we used 3 overlapping 6-month cycles per year.
1
In each 6-month cycle, eligible patients were required to have at least 1 prescription opioid filled; be continuously enrolled in Parts A, B, and D; and have no cancer nor be receiving hospice care. 1 We identified eligible beneficiaries who met CMS criteria as opioid overutilizers (ie, receiving prescription opioids with a mean daily morphine equivalent dose ≥90 mg and from >3 prescribers and >3 pharmacists or receiving a prescription of opioids with a mean daily morphine equivalent dose of ≥90 mg by >4 prescribers) 1 and those who had a diagnosis of OUD or overdose 3 in the same 6 months plus the subsequent 12 months to account for delays in OUD diagnoses. Linear regression was used to determine trends over time (SAS version 9.4; SAS Institute Inc). Statistical significance was defined as a 2-sided P<.05. This study was approved by the University of Florida Institutional Review Board with a waiver of informed consent.
Results | We identified between 142 036 and 190 320 eligible beneficiaries prescribed opioids across the 6-month measurement cycles from 2011 through 2014. The proportion of beneficiaries who met CMS overutilization criteria during any 6-month cycle ranged from 0.37% to 0.58%. The proportion who had a diagnosis of OUD or overdose during the 18-month follow-up increased from 3.91% in the first cycle to 7.55% in the last. We observed low sensitivity of the criteria, ranging from 4.96% (95% CI, 4.42%-5.58%) at the beginning of the study period to 2.52% (95% CI, 2.26%-2.81%) at the end (P for trend <.001) and positive predictive values ranged from 35.20% (95% CI, 32.14%-38.38%) to 50.94% (95% CI, 47.00%-54.86%; P for trend <.001). Specificity was greater than 99% in all cycles (Table) .
Discussion | Although the CMS criteria may target patients at true risk of OUD or overdose, they missed the majority of patients with OUD or overdose and flagged more than half of opioid prescription users as high risk who were not diagnosed as having OUD or overdose. The small positive 
